| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
24,295 |
18,816 |
$641K |
| 88307 |
|
4,472 |
3,946 |
$219K |
| 88304 |
|
7,928 |
6,482 |
$117K |
| 88173 |
|
742 |
582 |
$31K |
| 88342 |
|
1,981 |
1,437 |
$30K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
614 |
377 |
$25K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
1,084 |
1,040 |
$12K |
| 88112 |
|
903 |
716 |
$11K |
| 88302 |
|
847 |
724 |
$6K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
544 |
318 |
$6K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
540 |
522 |
$6K |
| 88311 |
|
934 |
812 |
$3K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
171 |
168 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
168 |
165 |
$2K |
| 88341 |
|
116 |
78 |
$2K |
| 85060 |
|
623 |
533 |
$2K |
| 88141 |
|
107 |
97 |
$944.71 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
38 |
38 |
$554.41 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
13 |
12 |
$184.11 |
| 3126F |
|
54 |
51 |
$0.00 |